A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma.

The article discusses a real-world observational study, NCT06659770, focusing on the efficacy and safety of zevorcabtagene autoleucel injection in patients with relapsed/refractory multiple myeloma. The study is a single-arm, open-label, multicenter, post-marketing, Phase IV, prospective, observational clinical trial aiming to evaluate the treatment's effectiveness in real-world settings. The primary study endpoints include overall survival rate at 24 months after infusion, while secondary endpoints focus on adverse events, response rates, and survival outcomes. The study is not yet recruiting participants, with an enrollment target of 200 individuals and a completion date set for December 31, 2027. [Extracted from the article]